Biotech Industry Will Look to Benefit From New U.S. Patent System
May 03 2012 - 8:20AM
Marketwired
Biotech stocks have continued to provide investors with strong
gains in 2012. The iShares NASDAQ Biotechnology Index (IBB) is up
nearly 20 percent year-to-date. The passage of the America Invents
Act will look to benefit the Biotechnology Industry going forward
"by enhancing patent quality and the efficiency, objectivity,
predictability and transparency of the U.S. patent system," BIO
President and CEO Jim Greenwood stated in a press release. The
Paragon Report examines investing opportunities in the
Biotechnology Industry and provides equity research on AEterna
Zentaris Inc. (NASDAQ: AEZS) and Zalicus Inc. (NASDAQ: ZLCS).
Access to full reports can be found at:
www.ParagonReport.com/AEZS www.ParagonReport.com/ZLCS
"Small biotechnology companies rely heavily on their patents to
attract investment," and "they will benefit from the improvements
to our nation's patent system made by this legislation," added
Greenwood. The America Invents Act (AIA) will shift the patent
system from a "first to invent" to a "first to file" system, the
first major change to the patent system in over 60 years. Under the
"first to invent" system the first inventor to file for a patent
will be awarded priority, regardless if the inventor was the first
to invent it. Most major countries are already following the "first
to file" patent system.
Paragon Report releases regular market updates on the
Biotechnology Industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.ParagonReport.com and
get exclusive access to our numerous stock reports and industry
newsletters.
AEterna Zentaris is an oncology and endocrinology drug
development company currently investigating treatments for various
unmet medical needs. AEterna Zentaris' pipeline encompasses
compounds at all stages of development, from drug discovery through
to marketed products. The company will announce its first quarter
2012 financial and operating results before market open on
Wednesday, May 9, 2012.
Zalicus, a biopharmaceutical company that discovers and develops
novel treatments for patients suffering from pain and
immuno-inflammatory diseases, recently announced it has completed
enrollment with 292 patients enrolled in the SYNERGY trial, a Phase
2b clinical trial designed to evaluate the safety and efficacy of
Synavive®, a low-dose glucocorticoid with the potential for
amplified immuno-inflammatory benefits, in patients with rheumatoid
arthritis.
Paragon Report provides Market Research focused on equities that
offer growth opportunities, value, and strong potential return. We
strive to provide the most up-to-date market activities. We
constantly create research reports and newsletters for our members.
The Paragon Report has not been compensated by any of the
above-mentioned companies. We act as independent research portal
and are aware that all investment entails inherent risks. Please
view the full disclaimer at: www.ParagonReport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Jul 2023 to Jul 2024